- Home
- CMAX vs CHRO Comparison
CMAX vs CHRO Comparison
Compare CMAX & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMAX
- CHRO
- Stock Information
- Founded
- CMAX 2011
- CHRO 2002
- Country
- CMAX United States
- CHRO United States
- Employees
- CMAX N/A
- CHRO N/A
- Industry
- CMAX Computer Software: Prepackaged Software
- CHRO
- Sector
- CMAX Technology
- CHRO
- Exchange
- CMAX Nasdaq
- CHRO Nasdaq
- Market Cap
- CMAX 7.6M
- CHRO 6.7M
- IPO Year
- CMAX N/A
- CHRO 2024
- Fundamental
- Price
- CMAX $1.99
- CHRO $0.95
- Analyst Decision
- CMAX Hold
- CHRO Strong Buy
- Analyst Count
- CMAX 2
- CHRO 1
- Target Price
- CMAX $33.20
- CHRO N/A
- AVG Volume (30 Days)
- CMAX 155.8K
- CHRO 12.3K
- Earning Date
- CMAX 08-09-2024
- CHRO 08-13-2024
- Dividend Yield
- CMAX N/A
- CHRO N/A
- EPS Growth
- CMAX N/A
- CHRO N/A
- EPS
- CMAX N/A
- CHRO N/A
- Revenue
- CMAX $784,551,000.00
- CHRO N/A
- Revenue This Year
- CMAX $13.01
- CHRO N/A
- Revenue Next Year
- CMAX $32.42
- CHRO N/A
- P/E Ratio
- CMAX N/A
- CHRO N/A
- Revenue Growth
- CMAX 9.06
- CHRO N/A
- 52 Week Low
- CMAX $1.55
- CHRO $0.59
- 52 Week High
- CMAX $85.20
- CHRO $6.00
- Technical
- Relative Strength Index (RSI)
- CMAX 36.54
- CHRO N/A
- Support Level
- CMAX $2.10
- CHRO N/A
- Resistance Level
- CMAX $2.43
- CHRO N/A
- Average True Range (ATR)
- CMAX 0.40
- CHRO 0.00
- MACD
- CMAX -0.14
- CHRO 0.00
- Stochastic Oscillator
- CMAX 1.17
- CHRO 0.00
About CMAX CareMax Inc.
CareMax Inc is a technology-enabled care platform providing value-based care and chronic disease management to seniors. It operates various owned medical centers that offer a comprehensive suite of healthcare and social services and a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians across the United States.
About CHRO Chromocell Therapeutics Corporation
Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.